Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 11/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14565979 | 0.86 | MCL1 (0.49) | EPHX1MCL1DPP4KMT2ACTSB | |
| SCHEMBL3261774 | 0.79 | NAAA (0.46) | NAAAEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL30942751 | 0.76 | MEN1 (0.37) | MEN1KMT2ACTSSCTSK | |
| SCHEMBL10536742 | 0.73 | NAAA (0.50) | NAAAEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL5076250 | 0.73 | MCL1 (0.42) | EPHX1MCL1 | |
| SCHEMBL4049386 | 0.71 | MCL1 (0.39) | MCL1DPP4MEN1KMT2ACTSB | |
| SCHEMBL9547591 | 0.71 | NAAA (0.47) | NAAAEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL5439490 | 0.70 | NAAA (0.51) | NAAAEPHX1EPHX2 | |
| SCHEMBL3482966 | 0.70 | NAAA (0.43) | NAAAEPHX1EPHX2MEN1KMT2A | |
| SCHEMBL7781007 | 0.69 | MCL1 (0.43) | NAAAEPHX1MCL1DPP4CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713815-A4 | PTH AGONISTS | SMITHKLINE BEECHAM CORP (US) | 2009-03-11 | — | — | EP | disclosed |
| US-20070099940-A1 | Pth agonists | SPEARING PAUL K | 2007-05-03 | — | — | US | disclosed |
| EP-1713815-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077959-A1 | PTH AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099940-A1 | Pth agonists | PTH1R, CALCR, SSTR3 | NAAA 2914/4885EPHX1 2807/4885MCL1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.